Natural killer cell containing exogenous mitochondrium and pharmaceutical composition comprising same
US12128070B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 23, 2021 |
| Grant date | Oct 29, 2024 |
| Priority date | — |
| Expiry date | Jan 26, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2239/48
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An NK cells and PBMC, both having increased cytotoxicity are provided. Particularly, NK cells and PBMC which have exogenous mitochondria introduced thereinto potentiate the immune system of the human body to enhance a therapeutic effect on infectious diseases or cancer. Therefore, the NK cells and PBMC can be used in a composition for prevention or treatment of infectious diseases and cancer. Specially, autogenous NK cells and PBMC guarantee stability without the incurrence of an immune reaction, and thus would be expected to have high commercial activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.